Is Kodiak Sciences Inc. (KOD) a Buy, Sell, or Hold?
Kodiak Sciences Inc.
NASDAQ:KOD
$41.955 USD
-$1.3 (-3.02%)
- Volume
- 402.4K
- Average Volume
- 757.33K
- Market Capitalization
- $2.22B
- P/E Ratio
- -10.06
- Dividend Yield
- 0.00%
- Price Target
- $59.50
- Year High
- $47.84
- Year Low
- $4.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.54
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Victor Perlroth |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KOD |
| CUSIP | 50015M109 |
| CIK | 0001468748 |
| Web | https://kodiak.com |
| Phone | 650 281 0850 |
| Currency | USD |
| Employees | 124 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.39 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.54 |
| Quick Ratio | 3.54 |
| Cash Ratio | 3.42 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.39 |
| Price / Cash Flow | -14.99 |
| Price / Book | 23.15 |
Price Target and Rating
| Average Stock Price Forecast | $59.50 |
| High Stock Price Forecast | $80.00 |
| Low Stock Price Forecast | $56.00 |
| Forecast Upside/Downside | -29.49% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.32 |
| Trailing P/E Ratio | -10.06 |
| PEG Ratio | 0.72 |
| P/E Growth | 0.72 |
| Net Income | $-229.97M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -253.85% |
| Return on Assets | -75.38% |
Financials Score
| AltmanZ Score | -2.62 |
| Piotroski Score | 1.00 |
| Working Capital | 125.68M |
| Total Assets | 306.01M |
| Ebit | -226.96M |
| Market Cap | 2.18B |
| Total Liabilities | 193.9M |
Poll Results
About Kodiak Sciences Inc. (NASDAQ:KOD) Stock
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a tripl ... et inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage
2026-06-16 12:09:59
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
2026-06-09 19:44:25
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
2026-06-04 12:07:09
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
2026-05-28 18:09:00
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
2026-05-17 15:57:13
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
2026-05-08 13:41:20
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
2026-05-07 16:00:00
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
2026-05-01 00:23:00
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.
Frequently Asked Questions
-
What is the current Kodiak Sciences Inc. (KOD) stock price?
-
Kodiak Sciences Inc.(NASDAQ:KOD) stock price is $41.955 in the last trading session. During the trading session, KOD stock reached the peak price of $47.84 while $4.56 was the lowest point it dropped to. The percentage change in KOD stock occurred in the recent session was --3.02% while the dollar amount for the price change in KOD stock was -$-1.3.
-
KOD's industry and sector of operation?
-
The NASDAQ listed KOD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KOD?
-
J. Pablo Velazquez-Martin | Chief Medical Officer
Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing
Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President
John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary
Almas Qudrat | Chief Quality Officer -
How many employees does KOD have?
-
Number of KOD employees currently stands at 124. KOD operates from 1200 Page Mill Road, Palo Alto, CA 94304, US.
-
Link for KOD official website?
-
Official Website of KOD is: https://kodiak.com
-
How do I contact KOD?
-
KOD could be contacted at phone #650 281 0850 and can also be accessed through its website. KOD operates from 1200 Page Mill Road, Palo Alto, CA 94304, US.
-
How many shares of KOD are traded daily?
-
The average number of KOD shares traded daily for last 3 months was 757.33K.
-
What is the market cap of KOD currently?
-
The market value of KOD currently stands at $2.22B with its latest stock price at $41.955